Business
ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules
CAMBRIDGE, Massachusetts, July 22, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to discovery and development of therapeutic antibodies targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzhiemer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD), today announced that it has raised $0.8 million at-the-market from an existing healthcare focused institutional investor. The com
About this update from Promis Neurosciences Inc.
[{"type":"image","alt":"ProMIS Neurosciences Inc.","displaySize":"","headline":null,"caption":"ProMIS Neurosciences Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":125,"url":"https://media.zenfs.com/en/globenewswire.com/cda799201650b516b39828de8c76948b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UIdpZ5Ja0S7N6QhO5P0RBA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cda799201650b516b39828de8c76948b","width":300,"height":125}},"lazy":false},{"type":"text","content":"CAMBRIDGE, Massachusetts, July 22, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to discovery and development of therapeutic antibodies targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzhiemer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD), today announced that it has raised $0.8 million at-the-market from an existing healthcare focused institutional investor.","length":498,"tagName":"p"},{"type":"text","content":"The company has entered into a definitive agreement for the issuance and sale of pre-funded warrants (the “Pre-Funded Warrants”) to purchase 984,736 common shares, no par value (the “Common Shares”). The Pre-Funded Warrants were sold at a price of $0.8124 per share, which represents the per share offering price for the Common Shares less a $0.0001 per share exercise price for each such Pre-Funded Warrant. The Pre-Funded Warrants will be immediately excercisable at a nominal exercise price of $0.0001 per share and may be exercised at any time until the Pre-Funded Warrants are exercised in full. The closing of the offering is expected to occur on or about July 24, 2025, subject to the satisfaction of customary closing conditions.","length":743,"tagName":"p"},{"type":"text","content":"The gross proceeds to ProMIS are expected to be approximately $0.8 million, before deducting certain offering expenses. ProMIS intends to use the net proceeds from the offering towards its further advancement of the clinical development of PMN310, its lead therapeutic candidate, as well as for working capital and other general corporate expenses.","length":348,"tagName":"p"},{"type":"text","content":"The securities above are being offering pursuant to a shelf registratio...